RoryShallisMD

PubMed

• Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eig...
  Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Talha Badar, Emily M Geramita, Vamsi K Kota, Alok Swaroop, Peter Doukas, D...> ;American Journal of Hematology. 2024 Apr 1
• 1 citations
  Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
  Shai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Ev...> ;Leukemia. 2024 Apr 1
• Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: resul...
  Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Adam S ...> ;Blood Cancer Journal. 2024 Feb 20
• A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or ...
  Jan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E Roe, Jonathan M Irish, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan ...> ;Annals of Hematology. 2024 Jan 1
• 2 citations
  Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia.
  Nikolai A Podoltsev, Rong Wang, Rory M Shallis, Jessica M Stempel, Mengyang Di, Natalia Neparidze, Amer M Zeidan, Scott F Huntington, Smith Giri, Sarah C Hull, Steven ...> ;Cancer Medicine. 2023 Sep 1
• 3 citations
  Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
  Shallis, R., Daver, N., Altman, J., Komrokji, R., Pollyea, D., Badar, T., Bewersdorf, J., Bhatt, V., de Botton, S., de la Fuente Burguera, A., Carraway, H., Desai, P.,...> ;The Lancet. Haematology. 2023 Sep 1
• Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
  Sangeetha Venugopal, Rory M Shallis, Amer M Zeidan> ;Expert Review of Anticancer Therapy. 2023 Jul 20
• 15 citations
  Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
  Daniel A Pollyea, Jessica K Altman, Rita Assi, Dale Bixby, Amir T Fathi, James M Foran, Ivana Gojo, Aric C Hall, Brian A Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori...> ;Journal of the National Comprehensive Cancer Network. 2023 May 1
• Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome.
  Cecily Allen, Samir Gautam, Wei Cheng, Alexander B Pine, Nikolai A Podoltsev, Amer M Zeidan, Alfred I Lee, Rory M Shallis> ;Acta Haematologica. 2023 Jan 1
• 1 citations
  Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence.
  Rory M Shallis, Rong Wang, Amer M Zeidan, Scott F Huntington, Natalia Neparidze, Jessica M Stempel, Lourdes M Mendez, Mengyang Di, Xiaomei Ma, Nikolai A Podoltsev> ;Blood Advances. 2023 Jul 11
• 2 citations
  Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
  Rong Wang, Rory M Shallis, Jessica M Stempel, Scott F Huntington, Amer M Zeidan, Steven D Gore, Xiaomei Ma, Nikolai A Podoltsev> ;Blood Advances. 2023 Mar 14
• 11 citations
  Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Cons...
  Talha Badar, Ehab Atallah, Rory Shallis, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Justin Grenet, Maximilian Stahl, Adam Duvall, Madelyn Burkart, Neil Palmisian...> ;Leukemia. 2023 Apr 1
• 2 citations
  Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.
  Mengyang Di, Jessica B Long, Shalin K Kothari, Tarsheen Sethi, Amer M Zeidan, Nikolai A Podoltsev, Rory M Shallis, Rong Wang, Xiaomei Ma, Scott F Huntington> ;Haematologica. 2023 Aug 1
• 3 citations
  Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
  Jan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, Aaron D Goldberg, Anthony Stein, Eytan M Stein, Guido Marcucci, Amer M Zeidan, Shai Shimony, Daniel J DeAngelo,...> ;Leukemia & Lymphoma. 2023 Jan 1
• 1 citations
  Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with-mutant acute myeloid leukemia.
  Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory M Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan> ;Leukemia & Lymphoma. 2023 Feb 1
• 5 citations
  Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azaci...
  Amer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory M Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten H...> ;Leukemia. 2023 Jan 1
• 8 citations
  TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
  Rory M Shallis, Naval G Daver, Jessica K Altman, Robert P Hasserjian, Hagop M Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H Wei, David A Sallman, Amer M Zeidan> ;Cancer. 2023 Jan 15
• 6 citations
  Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
  Jan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, Aaron D Goldberg, Anthony Stein, Eytan M Stein, Guido Marcucci, Amer M Zeidan, Shai Shimony, Daniel J DeAngelo,...> ;Leukemia Research. 2022 Nov 1
• 1 citations
  Concealed by the convenient: acquired von Willebrand syndrome in myeloproliferative neoplasm requires a thorough evaluation.
  Jessica M Stempel, Nikolai A Podoltsev, Amer M Zeidan, Alfred I Lee, Rory M Shallis> ;Annals of Hematology. 2022 Nov 1
• 4 citations
  Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period.
  Natalia Neparidze, Rong Wang, Amer M Zeidan, Nikolai A Podoltsev, Rory M Shallis, Xiaomei Ma, Amy J Davidoff, Scott F Huntington> ;Leukemia. 2022 Aug 1
• 2 citations
  Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis.
  Rory M Shallis, Steven D Gore> ;Leukemia & Lymphoma. 2022 Jul 1
• 24 citations
  Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
  Talha Badar, Ehab Atallah, Rory M Shallis, Aaron D Goldberg, Anand Patel, Yasmin Abaza, Jan P Bewersdorf, Antoine N Saliba, Guilherme Sacchi De Camargo Correia, Guru M...> ;American Journal of Hematology. 2022 Jul 1
• 6 citations
  Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis.
  Mengyang Di, Can Cui, Shalin K Kothari, Amer M Zeidan, Nikolai A Podoltsev, Natalia Neparidze, Rory M Shallis, Rong Wang, Xiaomei Ma, Scott F Huntington> ;Blood Advances. 2022 Jun 14
• 5 citations
  Are We Moving the Needle for Patients with-Mutated Acute Myeloid Leukemia?
  Rory M Shallis, Jan P Bewersdorf, Maximilian F Stahl, Stephanie Halene, Amer M Zeidan> ;Cancers. 2022 May 14
• 5 citations
  Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia.
  Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory M Shallis, Nikolai A Podoltsev, Scott F Huntington, Amer M Zeidan> ;Blood. 2022 Mar 17
• Join now to see all

Abstracts/Posters

• Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neopl...
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and ...
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Populati...
  Rory M Shallis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019